IMNN: R&D Day Highlights Potential for IMNN-001… [Yahoo! Finance]
Imunon, Inc. (IMNN)
Company Research
Source: Yahoo! Finance
On November 10, 2025, Imunon, Inc. (NASDAQ:IMNN) held an R&D day that featured presentations from ovarian cancer thought leaders and principal investigators from the Phase 3 OVATION 3 study and Phase 2 minimal residual disease (MRD) clinical trial. The presentation slides can be found here , and an overview of the presentations is given below. Premal Thaker, M.D. – Dr. Thaker was a principal investigator of the Phase 1 and Phase 2 trials for IMNN-001. She provided an overview of the unmet need in ovarian cancer, including the fact that the frontline standard of care has not changed for 30 years. In addition, Dr. Thaker showed how IMNN-001 increased cytokine levels at the tumor, along with an increase in anti-cancer dendritic cells and effector memory T cells. The following image shows how treatment with IMNN-001 results in a decrease in immunosuppressive biomarkers in the tumor (e.g., FoxP3, IDO-1, PD-1, etc.) that in turn results in an increase in the CD8+/CD4+ ratio. Dr. Thaker
Show less
Read more
Impact Snapshot
Event Time:
IMNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNN alerts
High impacting Imunon, Inc. news events
Weekly update
A roundup of the hottest topics
IMNN
News
- IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- IMUNON Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Imunon Q3 2025 Earnings Preview [Seeking Alpha]Seeking Alpha
- Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript [Seeking Alpha]Seeking Alpha
- IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian CancerGlobeNewswire
IMNN
Sec Filings
- 11/13/25 - Form S-8
- 11/13/25 - Form 10-Q
- 11/13/25 - Form 8-K
- IMNN's page on the SEC website